Paradigm Increases Stake in Olema Pharmaceuticals
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 22 2026
0mins
Source: Fool
- Share Acquisition: Paradigm Biocapital Advisors LP disclosed a purchase of 750,000 shares of Olema Pharmaceuticals in Q4 2025, representing an estimated $13.35 million trade that underscores confidence in the company.
- Increased Ownership: This acquisition raised Paradigm's stake in Olema to approximately 4.5%, highlighting its significance within the reported assets under management.
- Outstanding Stock Performance: As of February 17, 2026, Olema shares were priced at $14.08, reflecting a staggering 242% increase over the past year, significantly outperforming the S&P 500's 15% gain, indicating strong market recognition of its potential.
- Strong Financial Position: Olema ended the year with over $500 million in cash and successfully raised $200 million, providing ample financial support for upcoming pivotal moments in its clinical pipeline.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OLMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OLMA
Wall Street analysts forecast OLMA stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.440
Low
20.00
Averages
42.00
High
60.00
Current: 9.440
Low
20.00
Averages
42.00
High
60.00
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a novel, orally available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD). It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Its second product candidate in clinical development, called OP-3136, is a novel, orally available small molecule that potently and selectively inhibits KAT6, an epigenetic target that is dysregulated in breast and other cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Olema Pharmaceuticals Grants Stock Options to New Employees
- Stock Options Granted: Olema Pharmaceuticals granted stock options for 176,150 shares to six new employees effective June 1, 2026, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Grant Plan Details: The stock options are awarded under the 2022 Inducement Plan, vesting over four years with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, ensuring continuous employee engagement.
- Exercise Price Set: The options have an exercise price of $12.71 per share, matching the last reported sale price on June 1, 2026, which helps incentivize employees to align their interests with the company's growth.
- Clinical Development Progress: Olema focuses on targeted therapies for breast cancer and is advancing its lead candidate palazestrant through two Phase 3 clinical trials, indicating the company's potential and market prospects in innovative drug development.
See More
Eli Lilly's Retevmo Phase 3 Results Set New Oncology Standard
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 study demonstrates an 83% reduction in the risk of disease recurrence or death for Retevmo in early-stage RET fusion-positive non-small cell lung cancer patients, potentially establishing a new standard of care in the adjuvant setting, significantly enhancing the company's leadership in oncology.
- Survival Rate Improvement: The study also reports a 92% event-free survival rate at 24 months compared to 61% for placebo, a notable difference that not only boosts patient confidence in treatment but may also accelerate the adoption of genomic testing, further solidifying Lilly's market position in precision medicine.
- Strengthening Industry Trends: Lilly's success underscores the importance of precision medicine and biomarker-driven therapies in cancer treatment, likely attracting increased investor interest in other oncology companies with promising Phase 2 and Phase 3 catalysts, thereby driving innovation and growth across the industry.
- Future Outlook: With Lilly's breakthroughs in oncology, the market is keenly anticipating upcoming clinical data from other companies, including NeOnc Technologies and Olema Pharmaceuticals, which could further reshape investor perceptions of the oncology market.
See More
Olema Pharmaceuticals Reports Promising Phase 1 Data for OP-3136
- Significant Tumor Shrinkage: Olema Oncology reported that OP-3136 demonstrated tumor shrinkage in nearly two-thirds of evaluable patients, indicating its potential efficacy across multiple cancer types and supporting further development in metastatic breast cancer.
- Good Safety Profile: The clinical trial showed OP-3136 had a clean safety profile with no dose-limiting toxicities or treatment-related discontinuations observed, suggesting good tolerability even at higher doses, which may provide broader treatment options for patients.
- Dose-Related Exposure: The study indicated that OP-3136 achieved predictable, dose-related exposure, with drug levels meeting or exceeding efficacy targets at doses of 6 mg or higher, enhancing its attractiveness as a potential therapeutic option.
- Market Sentiment Shift: Despite a 46% drop in OLMA shares since the beginning of the year, the stock surged 205% over the past 12 months, and retail investor sentiment shifted from “bearish” to “extremely bullish,” reflecting optimism about the drug's prospects.
See More
Olema Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Olema Pharmaceuticals will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026, at 12:30 p.m. ET in a virtual fireside chat format, aiming to attract investor interest in its oncology research advancements.
- Global Healthcare Conference Participation: The company will also attend the Jefferies Global Healthcare Conference on June 3, 2026, at 8:45 a.m. ET in New York, further showcasing its innovative therapies in breast cancer treatment.
- Goldman Sachs Global Healthcare Conference: Olema plans to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 3:20 p.m. ET in Miami, using this opportunity to share updates on its clinical trial progress and future strategies.
- Clinical Trial Progress: Olema's lead product candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials, demonstrating the company's strong R&D capabilities and market potential in breast cancer treatment.
See More
Olema Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Performance: Olema Pharmaceuticals reported a Q1 GAAP EPS of -$0.52, beating expectations by $0.01, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Reserves: As of March 31, 2026, Olema's cash, cash equivalents, and marketable securities totaled $505.3 million, ensuring sufficient funding for future R&D and operations, thereby enhancing its financial stability.
- Market Engagement: Olema presented at the 2026 Citi Virtual Oncology Leadership Summit and Guggenheim Securities Emerging Outlook: Biotech Summit, demonstrating the company's proactive approach to engaging with investors and industry leaders to boost market awareness and investor confidence.
- Analyst Ratings: Seeking Alpha's Quant Rating on Olema Pharmaceuticals reflects market interest in its future performance, as current financial data still shows losses, yet investor interest in its potential growth opportunities remains strong.
See More
Olema Pharmaceuticals Grants Stock Options to New Employees
- Stock Options Granted: Olema Pharmaceuticals granted stock options for a total of 188,500 shares to four new employees effective April 1, 2026, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Exercise Price: The options have an exercise price of $15.12 per share, equal to the last reported sale price on April 1, 2026, aligning the interests of new employees with those of shareholders and promoting a culture of ownership.
- Vesting Schedule: The stock options vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, which is designed to improve employee retention and foster long-term stability within the company.
- Compliance Disclosure: Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in employee incentives, which can enhance investor confidence.
See More
Olema Pharmaceuticals Grants Stock Options to New Employees
- Stock Options Granted: Olema Pharmaceuticals granted stock options for 176,150 shares to six new employees effective June 1, 2026, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Grant Plan Details: The stock options are awarded under the 2022 Inducement Plan, vesting over four years with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, ensuring continuous employee engagement.
- Exercise Price Set: The options have an exercise price of $12.71 per share, matching the last reported sale price on June 1, 2026, which helps incentivize employees to align their interests with the company's growth.
- Clinical Development Progress: Olema focuses on targeted therapies for breast cancer and is advancing its lead candidate palazestrant through two Phase 3 clinical trials, indicating the company's potential and market prospects in innovative drug development.
See More
Eli Lilly's Retevmo Phase 3 Results Set New Oncology Standard
- Clinical Trial Success: Eli Lilly's LIBRETTO-432 study demonstrates an 83% reduction in the risk of disease recurrence or death for Retevmo in early-stage RET fusion-positive non-small cell lung cancer patients, potentially establishing a new standard of care in the adjuvant setting, significantly enhancing the company's leadership in oncology.
- Survival Rate Improvement: The study also reports a 92% event-free survival rate at 24 months compared to 61% for placebo, a notable difference that not only boosts patient confidence in treatment but may also accelerate the adoption of genomic testing, further solidifying Lilly's market position in precision medicine.
- Strengthening Industry Trends: Lilly's success underscores the importance of precision medicine and biomarker-driven therapies in cancer treatment, likely attracting increased investor interest in other oncology companies with promising Phase 2 and Phase 3 catalysts, thereby driving innovation and growth across the industry.
- Future Outlook: With Lilly's breakthroughs in oncology, the market is keenly anticipating upcoming clinical data from other companies, including NeOnc Technologies and Olema Pharmaceuticals, which could further reshape investor perceptions of the oncology market.
See More
Olema Pharmaceuticals Reports Promising Phase 1 Data for OP-3136
- Significant Tumor Shrinkage: Olema Oncology reported that OP-3136 demonstrated tumor shrinkage in nearly two-thirds of evaluable patients, indicating its potential efficacy across multiple cancer types and supporting further development in metastatic breast cancer.
- Good Safety Profile: The clinical trial showed OP-3136 had a clean safety profile with no dose-limiting toxicities or treatment-related discontinuations observed, suggesting good tolerability even at higher doses, which may provide broader treatment options for patients.
- Dose-Related Exposure: The study indicated that OP-3136 achieved predictable, dose-related exposure, with drug levels meeting or exceeding efficacy targets at doses of 6 mg or higher, enhancing its attractiveness as a potential therapeutic option.
- Market Sentiment Shift: Despite a 46% drop in OLMA shares since the beginning of the year, the stock surged 205% over the past 12 months, and retail investor sentiment shifted from “bearish” to “extremely bullish,” reflecting optimism about the drug's prospects.
See More
Olema Pharmaceuticals to Participate in Upcoming Investor Conferences
- Investor Conference Schedule: Olema Pharmaceuticals will participate in the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026, at 12:30 p.m. ET in a virtual fireside chat format, aiming to attract investor interest in its oncology research advancements.
- Global Healthcare Conference Participation: The company will also attend the Jefferies Global Healthcare Conference on June 3, 2026, at 8:45 a.m. ET in New York, further showcasing its innovative therapies in breast cancer treatment.
- Goldman Sachs Global Healthcare Conference: Olema plans to participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026, at 3:20 p.m. ET in Miami, using this opportunity to share updates on its clinical trial progress and future strategies.
- Clinical Trial Progress: Olema's lead product candidate, palazestrant (OP-1250), is currently in two Phase 3 clinical trials, demonstrating the company's strong R&D capabilities and market potential in breast cancer treatment.
See More
Olema Pharmaceuticals Q1 Earnings Beat Expectations
- Earnings Performance: Olema Pharmaceuticals reported a Q1 GAAP EPS of -$0.52, beating expectations by $0.01, indicating a slight improvement in financial performance despite remaining in a loss position.
- Cash Reserves: As of March 31, 2026, Olema's cash, cash equivalents, and marketable securities totaled $505.3 million, ensuring sufficient funding for future R&D and operations, thereby enhancing its financial stability.
- Market Engagement: Olema presented at the 2026 Citi Virtual Oncology Leadership Summit and Guggenheim Securities Emerging Outlook: Biotech Summit, demonstrating the company's proactive approach to engaging with investors and industry leaders to boost market awareness and investor confidence.
- Analyst Ratings: Seeking Alpha's Quant Rating on Olema Pharmaceuticals reflects market interest in its future performance, as current financial data still shows losses, yet investor interest in its potential growth opportunities remains strong.
See More
Olema Pharmaceuticals Grants Stock Options to New Employees
- Stock Options Granted: Olema Pharmaceuticals granted stock options for a total of 188,500 shares to four new employees effective April 1, 2026, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in the biopharmaceutical sector.
- Exercise Price: The options have an exercise price of $15.12 per share, equal to the last reported sale price on April 1, 2026, aligning the interests of new employees with those of shareholders and promoting a culture of ownership.
- Vesting Schedule: The stock options vest over four years, with 25% vesting on the first anniversary and the remainder in 36 equal monthly installments, which is designed to improve employee retention and foster long-term stability within the company.
- Compliance Disclosure: Olema is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in employee incentives, which can enhance investor confidence.
See More
